Featured video: Microparticles, breast cancer's secret weapon?

Read the article

Featured review: Molecular chess, hallmarks of anti-cancer drug resistance

Cree and Charlton_CC

Cree and Charlton_CC

The development of resistance to anti-cancer drugs is an ongoing problem which makes relapse inevitable for many cancer patients. Ian Cree and Peter Charlton review the known mechanisms leading to the acquisition of resistance, and discuss the importance of developing personalised therapeutic strategies to overcome it.

Read more

Articles

Recent articles RSS

  1. Study protocol

    CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0) (NCT03001596)

    Han Tang, Lijie Tan, Yaxing Shen, Hao Wang, Miao Lin, Mingxiang Feng, Songtao Xu, Weigang Guo, Cheng Qian, Tianshu Liu, Zhaochong Zeng, Yingyong Hou, Zhentao Yu, Hongjing Jiang, Zhigang Li, Chun Chen…

    Published on: 28 June 2017

View all articles

Aims and scope

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.

Editor

  • Dafne Solera, BioMed Central

Section Editors

  • Manami Inoue, University of Tokyo
  • Christophe Nicot, Kansas University Medical Center
  • Stephen P Povoski, The Ohio State University
  • Dirk Vordermark, Martin Luther University Halle-Wittenberg

BMC Series blog

View feed

Tweets

Advertisement

Submit a manuscript

Advertisement